MeCo Diagnostics

MeCo Diagnostics is a venture-backed startup with the only clinically validated test to match breast cancer patients with antifibrotic therapy—a breakthrough therapy that represents a fundamentally new way to target breast cancer. Our landmark Phase 2 randomized controlled trial revealed the greatest survival benefit ever reported for a targeted therapy in the history of breast oncology: We demonstrated a 62% reduction in risk of recurrence over 9.7 years on average for High MeCo Score patients, while Low MeCo Score patients experienced no benefit. MeCo Diagnostics traces its origins to the oldest observation in cancer biology: tumors often grow stiffer than surrounding tissue due to fibrosis, which produces a palpable lump. However, not all cancer cells are responsive to fibrotic stiffness, but those that are become “mechanically conditioned,” akin to deadly, microscopic machines that are programmed to wreak havoc as they spread throughout the body. Fortunately, there are both old and new antifibrotic drugs that can be repurposed to deprogram these dangerous cancer cells. This serendipity has empowered us to develop a commercially viable, biomarker-enabled drug repurposing approach that synergizes with standard-of-care treatment. Our lead asset, the MeCo Score, has been rigorously validated in 4 independent studies, comprising over 4000 patients in total, in partnership with oncologists at Cleveland Clinic, George Washington University, University of Arizona, University of Southern California, and the Spanish National Cancer Research Center. Moreover, since the MeCo Score can match patients with a generic-emergent drug, the cost of targeted antifibrotic therapy will soon be >10X cheaper than any other form of targeted therapy. Patients benefit from improved survival, while patients and payers both benefit from reduced treatment costs; thus, we are facilitating a unique win-win opportunity. Join our mission...